RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

ROCKVILLE, Md., April 9, 2018 -- (Healthcare Sales & Marketing Network) -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair an... Biopharmaceuticals, Ophthalmology, FDA RegeneRx Biopharmaceuticals, ReGenTree, Dry Eye
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news